Research programme: antiviral and antibacterial monoclonal antibody therapeutics - Valneva

Drug Profile

Research programme: antiviral and antibacterial monoclonal antibody therapeutics - Valneva

Alternative Names: Antiviral and antibacterial mAbs- Valneva; Antiviral and antibacterial monoclonal antibodies - Valneva; mAb D 005

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacterial infections; Cytomegalovirus infections; Influenza virus infections; Streptococcal infections

Highest Development Phases

  • No development reported Bacterial infections; Cancer; Cytomegalovirus infections; Influenza A virus infections; Streptococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-infections in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top